Becton, Dickinson and Company (NYSE:BDX) Releases Quarterly Earnings Results, Beats Expectations By $0.08 EPS

Becton, Dickinson and Company (NYSE:BDX) posted its quarterly earnings data on Thursday. The medical instruments supplier reported $4.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.07 by $0.08, FiscalAI reports. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The company had revenue of $5.27 billion for the quarter, compared to analysts’ expectations of $5.11 billion. During the same period in the previous year, the firm posted $3.96 EPS. Becton, Dickinson and Company’s revenue was up 5.4% compared to the same quarter last year.

Here are the key takeaways from Becton, Dickinson and Company’s conference call:

• BD reported Q4 revenue of $5.3 billion, up 5.6%, and adjusted EPS of $4.15, up 27.3%. For fiscal 2026, revenue increased 3.9% to $19.5 billion and adjusted EPS rose 6.7% to $12.70.
• Executives cited broad momentum in growth platforms, including Advanced Patient Monitoring, PureWick, biologic drug delivery, advanced tissue regeneration, and Rowa pharmacy automation. They also highlighted share gains in Alaris and strong adoption of the Incada AI platform, while noting these results reflect targeted commercial and capacity investments.
• Fiscal 2027 guidance calls for low-single-digit revenue growth and adjusted EPS of $13.10–$13.30, with operating margins roughly flat. Excluding an estimated 200-basis-point Alaris comparison headwind, revenue growth is expected to be mid-single-digit at the midpoint; Q1 growth is expected at the low end of the annual range.
• Full-year free cash flow rose 42% to $2.9 billion, and conversion improved to approximately 74%, including separation costs; BD expects another meaningful step-up in fiscal 2027. The company returned $3.6 billion to shareholders and said its capital allocation priorities include buybacks, debt reduction, and focused tuck-in acquisitions.
• BD agreed to invest $19 billion in the U.S. over several years, including $3 billion for manufacturing expansion; management said this is a reprioritization of planned investment, not incremental spending. Potential relief from future Section 232 tariffs is not included in guidance and depends on final rules and the company meeting agreed milestones.

Becton, Dickinson and Company Stock Performance

Shares of NYSE:BDX traded down $1.28 during midday trading on Friday, hitting $212.27. The stock had a trading volume of 2,172,550 shares, compared to its average volume of 1,599,485. Becton, Dickinson and Company has a 1 year low of $137.35 and a 1 year high of $214.88. The stock has a 50 day moving average price of $188.17 and a two-hundred day moving average price of $170.28. The company has a market capitalization of $58.49 billion, a PE ratio of 15.28, a P/E/G ratio of 13.39 and a beta of 0.22. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Thursday, December 10th will be paid a $1.06 dividend. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. The ex-dividend date is Thursday, December 10th. This represents a $4.24 annualized dividend and a dividend yield of 2.0%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 126.51%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of the stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the transaction, the executive vice president owned 19,720 shares in the company, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This trade represents a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 6,907 shares of company stock worth $1,269,128. 0.40% of the stock is owned by corporate insiders.

Becton, Dickinson and Company announced that its Board of Directors has authorized a stock buyback plan on Thursday, November 5th that permits the company to buy back 10,000,000 outstanding shares. This repurchase authorization permits the medical instruments supplier to buy up to 3.6% of its shares through open market purchases. Share repurchase plans are typically a sign that the company’s board believes its stock is undervalued.

Becton, Dickinson and Company News Roundup

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BD reported Q4 adjusted earnings of $4.15 per share and revenue of $5.27 billion, topping analyst expectations; revenue rose 5.4% year over year. BD fiscal 2026 results
• Positive Sentiment: The board raised the quarterly dividend 1% to $1.06 per share and authorized repurchases of up to 10 million shares, or about 3.6% of shares outstanding. Dividend increase and share repurchase authorization
• Positive Sentiment: Citigroup raised its price target to $241 and assigned a “buy” rating; Evercore ISI also lifted its target, to $230 from $210. Citigroup analyst rating Evercore ISI price target
• Neutral Sentiment: RBC raised its target to $225 but kept a “sector perform” rating, while Piper Sandler raised its target to $200 and maintained “neutral”—below the stock’s recent trading level. RBC analyst rating Piper Sandler price target
• Negative Sentiment: The main concern is the fiscal 2027 outlook: coverage reports say revenue-growth guidance came in just below expectations, tempering the impact of the Q4 beat and prompting investor concern. Fiscal 2027 guidance coverage

Analyst Ratings Changes

Several equities analysts have recently weighed in on BDX shares. Piper Sandler raised their price target on shares of Becton, Dickinson and Company from $175.00 to $200.00 and gave the stock a “neutral” rating in a research note on Friday. Stifel Nicolaus set a $195.00 target price on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $242.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday. Wolfe Research started coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, October 20th. They issued an “outperform” rating for the company. Finally, UBS Group initiated coverage on shares of Becton, Dickinson and Company in a research note on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Moderate Buy” and an average price target of $193.67.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies.

BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Its offerings serve hospitals, clinics, laboratories, researchers and pharmaceutical companies.